Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Advertisement

Avexitide cuts hypoglycaemic events by 55% in Phase 3 LUCIDITY trial in post-bariatric hypoglycaemia – Amylyx

Written by | 21 Nov 2026 | Conference Highlights

Amylyx Pharmaceuticals has presented results from the 16-week double-blind period of its Phase 3 LUCIDITY trial. The trial tested avexitide in people with post-bariatric hypoglycaemia (PBH) after Roux-en-Y gastric bypass (RYGB) surgery. The data were given as a late-breaking oral presentation at ObesityWeek 2026.

Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. In PBH, an exaggerated GLP-1 response triggers excessive insulin secretion, which leads to recurrent hypoglycaemia. Avexitide blocks the GLP-1 receptor on pancreatic beta cells to dampen this response.

Study design

LUCIDITY enrolled 78 adults with PBH after RYGB surgery. After a 3-week run-in, participants were randomised 3:2 to avexitide 90 mg or placebo, given subcutaneously once daily. All participants also received standard-of-care dietary management. Disease burden at baseline was substantial:

  • 68% reported daily hypoglycaemic symptoms
  • 47% had a history of loss of consciousness
  • 28% had a history of hypoglycaemia-related hospitalisation

More than 90% of participants completed the double-blind period.

Results

LUCIDITY met its primary endpoint. Avexitide reduced the composite rate of Level 2 and Level 3 hypoglycaemic events by 55% compared with placebo (least squares mean 0.55 vs 1.24 events per week, p=0.0000034).

All prespecified secondary event-rate endpoints were also met:

  • SMBG-confirmed Level 2 events fell by 63% (p=0.0000032)
  • Adjudicated Level 3 events fell by 47% (p=0.0016)
  • CGM-detected Level 2 events fell by 42% (p=0.00016)

Within each arm, events fell by 72.9% with avexitide and by 37.8% with placebo.

Safety

Adverse events were mainly gastrointestinal or at the injection site, and were generally mild to moderate. There were no deaths and no treatment-related serious adverse events. Body weight and fasting plasma glucose did not change in a clinically meaningful way.

The FDA has granted avexitide Breakthrough Therapy Designation for PBH. Amylyx plans to submit a New Drug Application by the end of the year. If approved, avexitide could be the first approved treatment for PBH. The 32-week open-label extension is ongoing.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.